Antisense Therapeutics Limited (ANP) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly. ANP has three products including ATL1102 injection for Multiple Sclerosis, ATL1103 injection for growth & sight disorders, and ATL1102 inhaled for asthma.
Antisense Therapeutics Limited belongs to Health Care sector and under industry of Pharmaceuticals. You can get more information about this company via their website: http://www.antisense.com.au.
This a small cap company with market cap of 94 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how anp dividend grows in the recent years.